ABSTRACT The immunologic response of graft re-
INTRODUCTION
Antilymphocyte globulin (ALG) is an extremely potent immunosuppressive agent in animals (1) . Recent evi- Received for publication 14 January 1970 and in revised form 2 April 1970. dence suggests that ALG is also effective in man and may improve the survival of human renal transplants (2) . Najarian, Simmons, Gewurz, Moberg, Merkel, and Moore (3) have reported that ALG used as the sole immunosuppressant prolongs the survival of skin grafts in man. The use of ALG in man, however, is complicated by immune reactions to the xenogeneic gamma globulin. A large proportion of patients treated with ALG become sensitized to xenogeneic protein and acute anaphylaxis and serum sickness have occurred (2, 4, 5) . Butler et al. (6) reported that in cardiac transplant patients treated with ALG immune clearance of 'Ilabeled ALG rapidly ensues. Studies recently published by Taub, Brown, Kochwa, Rubin, and Dameshek (7) and by Butler et al. (6) suggest that tolerance to xenogeneic gamma globulin may be achieved in man by treatment with aggregate-free xenogeneic gamma globulin. We have studied the immune -response of ALG-treated graft recipients to xenogeneic ALG and the effect of treatment with aggregate-free xenogeneic gamma globulin upon the subsequent immune response to ALG.
METHODS
Antilymphocyte globulin preparation. Horses, goats, and rabbits were immunized with human lymphoid cells (purified blood lymphocytes, splenic cells, and thymic cells). Two immunization schedules were followed: (a) a twopulse intravenous course (8) and (b) a course of multiple subcutaneous inoculations with Freund's adjuvant (9) . Anti-lymphocyte serum was absorbed with one-tenth its volume of human plasma and three times with human erythrocytes representing 30, 20 , and 10% of its volume. ALG was prepared from absorbed whole serum by precipitation with 50% cold saturated ammonium sulfate followed by batch DEAE-cellulose chromatography. The isolated gamma globulin was centrifuged for 60 min at 100,000 g, passed through a 0.22 ,um millipore membrane, The Journal of Clinical Investigation Volume 49 1970 and stored at 4VC before use. Tests for sterility and pyrogenicity were performed on each batch of ALG. ALG so prepared formed a single precipitin arc on immunoelectrophoresis with rabbit anti-horse serum having the migration characteristic of gamma globulin. The cytotoxicity titer, as measured by trypan blue dye exclusion, ranged from 1: 64 to 1: 512. Several batches of ALG had mitogenic activity when added to human lymphocytes in culture.
Preparation of aggregate-free equine gamma globulin. Commercial equine gamma globulin (Pentex Cohn fraction II) was purified by batch elution from DEAE-cellulose and lyophilized. The purified equine gamma globulin was dissolved in physiologic saline immediately before use and aggregated protein removed by centrifugation for 60 min in a Beckman Ti 50 rotor at 45,000 rpm (gas= 133,500). Before treatment patients were evaluated for anaphylactic sensitivity to equine gamma globulin by intradermal skin tests. Patients having negative skin tests were given 50 mg/kg aggregate-free equine gamma globulin.
Iodination of gamma globulin. ALG from a single batch of horse, rabbit, or goat ALG and autologous human gamma globulin were labeled with 'I by the chloramine T method as described by McConahey and Dixon (10) . The iodine product was dialyzed against 0.15 M sodium chloride containing 0.01 M sodium phosphate buffer, pH 7.2. After dialysis more than 98% of the radioactivity was precipitated with 10% trichloroacetic acid. The iodinated protein retained its characteristic immunoelectrophoretic and gel filtration properties. Iodinated rabbit ALG injected intravenously into two rabbits was found to have a serum half-life of 5.3 and 6.1 days. This disappearance rate is compatible with data in the literature (11) , and suggested that only minimal denaturation of the gamma globulin had occurred as a result of the iodination procedure. Before administration to patients the iodinated ALG was sterilized and centrifuged as described above.
Immune clearance of ALG-125I. 0.1 ,uCi of ALG-'1'I per kg was administered intravenously (10-50 tig of protein per /Ci) to patients. HI uptake by the thyroid was blocked by the administration of a saturated solution of potassium iodine, 10 drops twice daily. Daily clotted blood samples were obtained for the following 14 days. A 2 ml serum sample from each of the 14 days of study was counted in a sodium iodide crystal well counter. After the initial 48 hr, the decline in serum radioactivity followed first order kinetics. The halflife of iodinated ALG was calculated from the decline in serum radioactivity after the first 48 hr. 1 ml of serum obtained 1 hr after intravenous administration of ALG-'I was analyzed by gel filtration through a 2.5 X 40 cm column of Sephadex G 200 using 0.15 M sodium chloride as eluant.
Circulating antibody to xenogeneic gamma globulin in ALG-treated patients. Serum samples were examined for the presence of antibody to xenogeneic gamma globulin. Precipitating antibody was assayed by immunodiffusion in gel (12) ; complement fixing antibody was assayed by the micromethod of Wasserman and Levine (13) ; and hemagglutinating antibody was assayed by the passive hemagglutinating method of Stavitsky (14) using tanned human type O red cells to which gamma globulin was absorbed.
Immunosuppressive therapy in graft recipients. Graft recipients were initially treated after transplantation with azathioprine (2-4 mg/kg), corticosteroid (1-2 mg/kg of prednisolone), and ALG. The subsequent dosage of azathioprine and corticosteroid was determined by the clinical state of graft function. Most patients were given 20-200 mg of ALG per day during the first 3-4 wk after transplantation and the dose was subsequently tapered so that most of the outpatients were receiving 20 mg/wk after 3 months. Several patients were studied more than 3 months after transplantation and had received more than one preparation of ALG. Patients E.T., P.S., J.K., and C.H. as well as the five patients pretreated with aggregate-free gamma globulin received the same preparation of ALG. Initially most of the ALG was administered subcutaneously but more recently as larger doses of ALG have been used the intravenous route has been employed.
RESULTS
Survival of ALG-l5I in patients before and after ALG therapy. The first immunological response studied in graft recipients was the clearance of ALG from the serum. The survival of ALG-Iz in serum was studied in four patients not previously treated with ALG. Two patients (M.P. and J.V.) were studied before transplantation and were not receiving immunosuppressive therapy. Two patients (W.C. and W.Ch.) were studied immediately after transplantation and were receiving azathioprine and corticosteroids and ALG for a part of the study period. The serum half-lives of these four patients ranged from 6.0 to 8.3 days with no significant difference attributable to immunosuppressive therapy. Clearance of ALG-'I was then studied in 15 graft recipients treated with ALG for a minimum of 4 wk. Of these 15 patients, 13 patients were renal graft recipients and 2 were cardiac graft recipients. patients who had received over 4 wk of ALI fore clearance studies. The calculated serun each of these patients and the cumulative before survival study are given in Table I (G.M.) of these patients on ALG treatme clearance of ALG-'I from the serum. Th tient had received small doses (20 mg/wk) 9 months before the clearance study. Hi dose of ALG before the survival study, I comparable to several other graft recipi No known immunologic deficiency was r this patient. A highly significant difference in the mean serum survival of ALG-w'I M tween the patients studied before (ti = 7.
after 4 wk of ALG therapy (ti = 3.8 day heart graft recipients had the most rapid ALG-'I (ti = 15 and 29 hr). These E treated nmore intensively with ALG than w graft recipients. One patient (W.Ch.) was at the inception of ALG therapy and after ALG treatment. His serum half-life of l 6.8 days initially and decreased to 3.6 da later. (Table II, index of the presence of immune complexes. The size distribution of radioactivity in blood 1 hr after intravenous administration of ALG-'I was studied by gel filtration through Sepadex G 200. The vast bulk of radioactivity in whole blood was found in the plasma. Less than 1% of the whole blood radioactivity was associated with the washed cell pellet. The distribution of radioactivity among the serum proteins was examined by Sephadex G 200 gel filtration of whole serum, Studies were carried out on (a) normal serum mixed in vitro with iodinated ALG, (b) serum obtained 1 hr after intravenous administration of ALG-'I to the patient (G.B.) with the most rapid serum clearance of ALG, and (c) serum obtained 1 hr after ALG-JI administration to the patient (G.M.) with the least rapid serum clearance of ALG. The elution of radioactivity after gel filtration in these three situations is shown in Fig. 2 .
The radioactivity after in vitro mixture of normal serum and ALG-'I has the elution characteristic of 7S gamma globulin, Ka. = 0.26, (15) . In contrast serum from patient G.B. had a significant portion of radioactivity present in the void volume. Slower peaks of radioactivity with K.y values greater than the starting material may represent degradation products of infused ALG. A significant fraction of radioactivity was found in the void volume in two patients (G.B. and W.P.) both of whom had a very rapid clearance of ALG-JI. Serum from several remaining patients showed a peak of radioactivity with shouldering toward the late fractions. Aggregation of ALG by serum from G.B. and W.P. could be demonstrated by gel filtration after in vitro incubation of ALG-'I and serum. The elution of radioactivity after gel filtration of such an in vitro mixture is shown in Fig. 3 . The amount of radioactivity that appeared in the void volume seemed to be limited by the amount of serum and not the amount of ALG-'I. (Table III) . The hemagglutination titer in four patients not treated with ALG and eight normal volunteers is shown in Table IV . The occasional occurrence of low titers in these individuals may be a nonspecific reaction or alternatively indicate that low titers of circulating antibody in certain patients may not result from specific immunization to ALG. A correlation between the titer of hemagglutinating antibody activity and the rate of clearance of ALG-'I can be seen from the data. In general, the higher titers of antibody were found in patients with the most rapid clearance of ALG. The serum from four patients (G.B., W.P., S.B., and P.S.) were tested for hemagglutinating activity against rabbit, goat, and horse gamma globulin. The results are shown in Table IV . Influence of pretreatment with aggregate-free equine gamma globulin on the survival of ALG-"'I and antibody development after ALG treatment in graft recipients. The demonstration that rapid sensitization to xenogeneic gamma globulin follows ALG therapy implies that the induction of tolerance to ALG may have clinical benefits. Five renal graft recipients have been pretreated with aggregate-free equine gamma globulin before transplantation and the initiation of ALG therapy. These patients received 50 mg/kg aggregate-free equine gamma globulin by intravenous infusion 1-4 days before transplantation and 3-7 days before the initiation of ALG therapy. Clearance of ALG-'I was studied 3-8 wk after transplantation. The cumulative dose of ALG before survival study and the calculated serum half-life of ALG-'I are given in Table V . The mean survival of ALG-'I in this group of patients (ti = 5.9 days) is significantly (P < 0.02) longer than that seen in the group of ALG-treated renal graft recipients (ti = 3.8 days) described in Table I . The mean serum survival appears to be shorter than that found in the patients not previously treated with ALG; however, the difference is not statistically significant (P > 0.10). Serum obtained from three patients 1 hr after ALG-'I administration did not show any radioactivity in the void volume when subjected to gel filtration on Sephadex G 200. Except for the occurrence of fever 4 hr after infusion of aggregate-free gamma globulin in one patient, no untoward effects of aggregate-free gamma globulin administration were noted. One patient (P.F.) had an open renal biopsy 5 wk after the aggregate-free equine gamma globulin infusion and ALG therapy. No deposits of gamma globulin or complement were found in the glomeruli by immunofluorescence staining techniques. Serum from the five pretreated patients showed insignificant titers of hemagglutinating activity (Table  III) . In two cases no antibody activity was detectable and in three hemagglutinating activity was found only in undiluted serum specimen.
DISCUSSION
Since the introduction of antiserum therapy of human disease at the turn of the century, investigators have repeatedly documented the dangers of serum therapy in man (16) . The administration of large doses of xenogeneic protein may lead to a rather typical clinical syndrome, serum sickness, in both man (17) and experimental animals (18) . We (18) . Circulating immune complexes were demonstrated in the serum of two patients. In addition one cardiac transplant recipient showed evidence of deteriorating renal function during ALG therapy. In this patient creatinine clearance fell markedly during ALG therapy, rose when ALG was discontinued, and fell again when ALG therapy was restarted. No immunofluorescent study was made at postmortem examination in this case and the pathogenesis of the renal failure remains unproven. Immune complex nephritis, however, has been documented during ALG therapy in man (5) and experimental animals (22) .
The effect of circulating antibody to ALG and the resulting rapid clearance of ALG from the serum on the immunosuppressive potency of ALG is uncertain. Some investigators suggest that sensitization to ALG is associated with a loss of immunosuppressive potency (23) (24) (25) . On the other hand some workers (26, 27) have found no loss in immunosuppressive potency of ALG despite actively induced anti-ALG antibody. Nonetheless, the induction of tolerance to xenogeneic gamma globulin before ALG therapy is acknowledged to potentiate its immunosuppressive potency in animals. Tolerance to ALG has been produced in animals by the transfer of biofiltered gamma globulin (26) , administration of normal xenogeneic serum in the neonatal period (27, 28) , and the administration of aggregate-free (ultracentrifuged) gamma globulin (21, 29 ). It has not been possible to induce tolerance to ALG in man with ultracentrifuged ALG (6) although both Taub et al. (7) and Butler et al. (6) have offered evidence that the administration of aggregate-free gamma globulin be-fore ALG prevents immunologic reactivity of patients to ALG.
The present study demonstrates that treatment of graft recipients with aggregate-free gamma globulin prevents subsequent rapid immune clearance of ALG and the development of significant titers of antibody to ALG after the initiation of ALG therapy. No untoward effects of treatment with aggregate-free gamma globulin were found. The induction of tolerance to xenogeneic gamma globulin should prevent the occurrence of serum sickness during ALG therapy and may potentially augment its immunosuppressive potency.
